Inhibition of matrix metalloproteinases ameliorates blood-brain barrier disruption and neuropathological lesions caused by avirulent Semliki Forest virus infection

Veterinary Immunology and Immunopathology

Volumn 94, Issue 3-4, 2003, Pages 185-190

  Keogh, Brian ^a,b   Sheahan, Brian J ^b   Atkins, Gregory J ^a   Mills, Kingston H G ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Blood brain barrier; Fibrinogen; Matrix metalloproteinases; Neuropathology; Semliki Forest virus

Indexed keywords

FIBRINOGEN; GELATINASE A; GELATINASE B; ILOMASTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMYELINATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MOUSE; NERVE CELL NECROSIS; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPIL; NONHUMAN; PROTEIN EXPRESSION; SEMLIKI FOREST ALPHAVIRUS; VIRUS INFECTION; VIRUS STRAIN;

ANIMALIA; RABBIT FIBROMA VIRUS; SEMLIKI FOREST VIRUS;

EID: 0142092735     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2427(03)00082-5     Document Type: Article

References (27)

1. Amor S., Scallan M., Morris M., Dyson H., Fazakerley J. Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis. J. Gen. Virol. 77:1996;281-291.
2. Atkins G., Sheahan B., Liljestrom P. The molecular pathogenesis of Semliki Forest virus: a model virus made useful? J. Gen. Virol. 80:1999;2287-2297.
3. Balluz I.M., Glasgow G., Killen H.M., Mobruk M.J.E.M.F., Sheahan B.J., Atkins G.J. Virulent and avirulent strains of Semliki Forest virus show similar cell tropism for the murine central nervous system but differ in the severity and rate of induction of cytolytic damage. Neuropathol. Appl. Neurobiol. 19:1993;233-239.
4. Barrett P.N., Sheahan B., Atkins G.J. Isolation and preliminary characterization of Semliki Forest virus mutants with altered virulence. J. Gen. Virol. 49:1980;141-147.
5. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol. 7:1995;728-735.
6. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
7. Chandler S., Miller K., Clements J., Lury J., Corkill L., Anthony D., Adams S., Gearing A. Matrix metalloproteinases, tumour necrosis factor and multiple sclerosis: an overview. J. Neuroimmunol. 72:1997;155-161.
8. Chapman H.A. Role of enzyme receptors and inhibitors in regulating proteolytic activities of macrophages. Ann. NY Acad. Sci. 624:1991;87-96.
9. Clements J., Cossins J., Wells G., Corkill D., Helfrich K., Wood M., Pigott R., Stabler G., Ward G., Gearing A., Miller K. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 74:1997;85-94.
10. Eralinna J.P., Soilu-Hällinen M., Roytta M., Hukkanen V., Salmi A.A., Salonen R. Blood-brain barrier breakdown and increased intercellular adhesion molecule (ICAM-1/CD54) expression after Semliki Forest (A7) virus infection facilitates the development of experimental allergic encephalomyelitis. J. Neuroimmunol. 66:1996;103-114.
11. Fleeton M.N., Liljestrom P., Sheahan B.J., Atkins G.J. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J. Gen. Virol. 81:2000;749-758.
12. Ghorpade A., Persidskaia R., Suryadevara R., Che M., Juan Liu X., Persidsky Y., Gendelman H. Mononuclear phagocyte differentiation, activation, and viral infection regulate matrix metalloproteinase expression: implications for human immunodeficiency virus type-1 associated dementia. J. Virol. 75:2001;6572-6583.
13. Gijbels K., Galardy R., Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J. Clin. Invest. 94:1994;2177-2182.
14. Graesser D., Mahooti S., Madri J. Distinct roles for matrix metalloproteinase-2 and α4-integrin in autoimmune T cell extravasation and residency in brain parenchyma during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 109:2000;121-131.
15. Hartung H.P., Kieseier B. The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J. Neuroimmunol. 107:2000;140-147.
16. Jankowski M.K., Ogilvie G.K., Lana S.E., Fettman M.J., Hansen R.A., Powers B.E., Mitchener K.M., Lovett S.D., Richardson K.L., Parsley L., Walton J.A. Matrix metalloproteinase activity in tumour, stromal tissue and serum from cats with malignancies. J. Vet. Intern. Med. 16:2002;105-108.
17. Johnston J.B., Jiang Y., van Marle G., Mayne M.B., Ni W., Holden J., McArthur J.C., Power C. Lentivirus infection in the brain induces matrix metalloproteinase expression: role of envelope diversity. J. Virol. 74:2000;7211-7220.
18. Keogh B., Atkins G., Mills K.H.G., Sheahan B.J. Avirulent Semliki Forest virus replication and pathology in the central nervous system is enhanced in IL-12-defective and reduced in IL-4-defective mice: a role for Th1 cells in the protective immunity. J. Neuroimmunol. 125:2002;15-22.
19. Khuth S.T., Akaoka H., Pagenstecher A., Verlaeten O., Belin M.F., Giraudon P., Bernard A. Morbillivirus infection of the mouse central nervous system induces region-specific upregulation of MMPs and TIMPs correlated to inflammatory cytokine expression. J. Virol. 75:2001;8268-8282.
20. Kuroki K., Kreeger J.M., Cook J.L., Tomlinson J.L., Johnson G.C., Pace L.W., Turnquist S.E., Turk J.R., Ramos J.A., Miller M.A. Immunohistochemical analysis of matrix metalloproteinase-1, -3 and -13 in naturally occurring cartilaginous tumours of dogs. Am. J. Vet. Res. 63:2002;1285-1291.
21. Morris M., Dyson H., Baker D., Harbige L., Fazakerley J., Amor S. Characterisation of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection. J. Neuroimmunol. 74:1997;185-197.
22. Morris-Downes M.M., Phenix K.V., Smyth J., Sheahan B.J., Lileqvist S., Mooney D.A., Liljestrom P., Todd D., Atkins G.J. Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine. 19:2001;1978-1988.
23. Papparella S., Restucci B., Paciello O., Maiolino P. Expression of matrix metalloproteinase-2 (MMP-2) and the activator membrane type 1 (MT1-MMP) in canine mammary carcinomas. J. Comp. Pathol. 126:2002;271-276.
24. Rosenberg G.A., Kornfeld M., Estrada E., Kelley R.O., Liotta L.A., Stetler-Stevenson W.G. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res. 576:1992;203-207.
25. Sheahan B., Gates M., Atkins G. Oligodendrocyte infection and demyelination produced in mice by the M9 mutant of Semliki Forest virus. Acta Neuropathol. (Berl.). 60:1983;257-265.
26. Sheahan B.J., Ibrahim M., Atkins G.J. Demyelination of olfactory pathways in mice following intranasal infection with the avirulent A7 strain of Semliki Forest virus. Eur. J. Vet. Pathol. 2:1996;117-125.
27. Soilu-Hänninen M., Eralinna J., Hukkanen V., Roytta M., Salmi A., Salonen R. Semliki Forest virus infects mouse brain endothelial cells and causes blood-brain barrier damage. J. Virol. 68:1994;6291-6298.